Drugs / Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Cell therapy targets CD19 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01865617 | May 2013 → Mar 2021 | adult acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01865617 ↗ |
| Action | Deplete | “if the adoptive transfer of CD19 CAR-T cells results in depletion of CD19+ B cells in vivo” NCT01865617 ↗ |
| Modality | Cell therapy | “Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR)” PMID 30728140 ↗ Feb 2019 |
| Route | Intravenous | “autologous T cells intravenously (IV) over 20-30 minutes on day 0” NCT01865617 ↗ |
| Target | CD19 | “Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR)” PMID 30728140 ↗ Feb 2019 |